Venous thrombosis is a common disorder with an annual incidence of around 1-2 cases per 1.000 individuals and is the third leading cause of cardiovascular morbidity and mortality in developed countries.1-4 Thrombosis may arise in any section of the venous system, but it typically occurs in the deep veins of the lower extremities. The major concern in these patients is pulmonary embolism, which can be fatal. A more common, but often disabling, complication of deep vein thrombosis and its sequelae is the post-thrombotic syndrome.5 Rarely, thrombosis may involve other venous sites. One of these uncommon manifestations of thrombosis is located in the splanchnic veins, which is accompanied by a considerable morbidity and mortality.

, ,
Alexon, Bayer, Celgene, Dutch Heart Foundation, Fonds Wetenschappelijk Onderzoek van de MPN Stichting, J.E. Jurriaanse Stichting, Novartis, Pfizer, Shire
F.W.G. Leebeek (Frank) , H.L.A. Janssen (Harry)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Smalberg, J. (2012, January 12). Budd-Chiari Syndrome and Portal Vein Thrombosis: Etiology and Treatment. Retrieved from